Insider Buying: Alumis (NASDAQ:ALMS) Director Purchases 588,235 Shares of Stock

Alumis Inc. (NASDAQ:ALMS) Director Srinivas Akkaraju purchased 588,235 shares of the stock in a transaction on Friday, January 9th. The shares were purchased at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the transaction, the director owned 1,853,488 shares in the company, valued at $31,509,296. This trade represents a 46.49% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Srinivas Akkaraju also recently made the following trade(s):

• On Friday, December 5th, Srinivas Akkaraju acquired 186,377 shares of Alumis stock. The stock was purchased at an average price of $9.84 per share, with a total value of $1,833,949.68.
• On Thursday, December 4th, Srinivas Akkaraju bought 66,027 shares of Alumis stock. The stock was purchased at an average price of $8.18 per share, for a total transaction of $540,100.86.
• On Wednesday, December 3rd, Srinivas Akkaraju purchased 100,000 shares of Alumis stock. The stock was acquired at an average price of $7.75 per share, for a total transaction of $775,000.00.
• On Tuesday, December 2nd, Srinivas Akkaraju purchased 96,000 shares of Alumis stock. The shares were acquired at an average cost of $7.55 per share, with a total value of $724,800.00.
• On Monday, December 1st, Srinivas Akkaraju acquired 86,350 shares of Alumis stock. The shares were acquired at an average price of $7.46 per share, with a total value of $644,171.00.
• On Friday, November 28th, Srinivas Akkaraju bought 38,702 shares of Alumis stock. The shares were acquired at an average cost of $7.64 per share, with a total value of $295,683.28.
• On Wednesday, November 26th, Srinivas Akkaraju bought 48,537 shares of Alumis stock. The shares were acquired at an average price of $7.64 per share, with a total value of $370,822.68.
• On Thursday, November 20th, Srinivas Akkaraju purchased 125,743 shares of Alumis stock. The shares were bought at an average cost of $7.20 per share, for a total transaction of $905,349.60.
• On Wednesday, November 19th, Srinivas Akkaraju acquired 137,772 shares of Alumis stock. The shares were bought at an average price of $6.56 per share, with a total value of $903,784.32.
• On Tuesday, November 18th, Srinivas Akkaraju acquired 102,652 shares of Alumis stock. The stock was bought at an average cost of $6.05 per share, with a total value of $621,044.60.

Alumis Stock Performance

Alumis stock traded up $1.02 during midday trading on Tuesday, hitting $22.11. 4,660,878 shares of the company were exchanged, compared to its average volume of 12,771,338. The firm has a market capitalization of $2.31 billion, a PE ratio of -5.46 and a beta of -2.09. Alumis Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $23.00. The business has a fifty day simple moving average of $9.54 and a two-hundred day simple moving average of $6.08.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. As a group, equities analysts expect that Alumis Inc. will post -8.51 earnings per share for the current year.

Hedge Funds Weigh In On Alumis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALMS. Russell Investments Group Ltd. raised its holdings in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after purchasing an additional 4,894 shares in the last quarter. Kera Capital Partners Inc. acquired a new stake in Alumis in the second quarter valued at $32,000. Police & Firemen s Retirement System of New Jersey lifted its holdings in Alumis by 199.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock worth $32,000 after buying an additional 7,165 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Alumis by 173.7% during the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after acquiring an additional 7,467 shares in the last quarter. Finally, Western Wealth Management LLC purchased a new position in shares of Alumis in the 2nd quarter valued at about $36,000.

Analyst Ratings Changes

Several brokerages have recently issued reports on ALMS. Wells Fargo & Company lifted their target price on shares of Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday, January 6th. Citigroup reiterated an “outperform” rating on shares of Alumis in a report on Tuesday, January 6th. UBS Group reiterated an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. HC Wainwright restated a “buy” rating and issued a $40.00 target price (up previously from $20.00) on shares of Alumis in a research report on Friday. Finally, Morgan Stanley lifted their price target on Alumis from $22.00 to $33.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Alumis News Summary

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Major insider/investor purchase — Foresite (and director James Tananbaum) bought 411,764 shares at an average of $17.00 (≈$7.0M), increasing their stake by 7.78% to 5,702,536 shares; large insider buys often signal confidence and can drive short‑term buying interest. Insider SEC Filing
• Positive Sentiment: Media coverage amplifying the buy — multiple outlets (Investing.com, InsiderTrades, MarketBeat) picked up the trade, increasing visibility and likely contributing to upward price momentum as retail and momentum traders react. Investing.com: Foresite buys ALMS
• Neutral Sentiment: Analyst coverage is favorable — recent research notes (UBS, Oppenheimer, Guggenheim, Wells Fargo, Citi) show multiple “outperform/buy” ratings and raised price targets (consensus target cited ~ $37.67). Positive analyst commentary supports sentiment but valuation and clinical execution remain key. MarketBeat: ALMS coverage
• Neutral Sentiment: Institutional position moves — various institutional holders (Vanguard, Samsara Biocapital, Trium Capital, Orbimed) have recently adjusted stakes; these shifts can provide liquidity and longer-term support but do not guarantee near-term price direction.
• Negative Sentiment: Underlying fundamentals and recent results are still weak — the company reported an earnings miss (Q3: EPS -$1.06 vs. -$0.92 est.; revenue $2.07M vs. $3.14M) and analysts still expect negative EPS for the year, so upside depends on clinical progress and execution rather than current revenue. MarketBeat: ALMS earnings and analyst notes

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.